Terapias Dirigidas para la Oncología de Precisión

Home
Investigación
Cáncer
Terapias Dirigidas para la Oncología de Precisión

Publicaciones

2025

Ballesteros-González, I, Hernández-Navas, I, Brehey, O, Lechuga, CG, Salmon, M, Scotece, M, Velasco-Vicente, R, Flores-Gomez, AA, Cebriá, A, Simon-Carrasco, L, Jiménez, G, Musteanu, M, Guerra, C, Domínguez, O, Caleiras, E, Blanco-Aparicio, C, Pons, T, Ferrer, I, Paz-Ares, L, Torres-Ruiz, R, Rodríguez-Perales, S, Barbacid, M, Drosten, M (2025).

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

EMBO Molecular Medicine. Article. 17(12):3377-3406.
[doi:10.1038/s44321-025-00326-z]

Otero-Rosales, M, Alvarez-González, M, Pazos, I, de Luxán-Delgado, B, Del Marro, S, Pozo-Agundo, E, Rodríguez-Santamaría, M, López-Fernández, A, Corte-Torres, D, Granda-Díaz, R, Alvarez-Teijeiro, S, Fernández-Vega, I, Lorz, C, García-Escudero, R, Rodrigo, JP, Tzelepis, K, Vassiliou, G, Ferrer, I, Alvarez-Fernández, M, García-Pedrero, JM, Hermida-Prado, F (2025).

CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer

Signal Transduction and Targeted Therapy. Article. 10(1).
[doi:10.1038/s41392-025-02452-z]

Redin, E, Otegui, N, Santos, M, Leon, S, Redrado, M, Serrano, D, de Pierola, EF, Russo-Cabrera, JS, Ferrer, I, Olmedo, M, Diaz-Lagares, A, Houry, M, Vicent, S, Vilalta, A, Mondelo-Macía, P, García-González, J, León-Mateos, L, Gonzalez, A, Paz-Ares, L, López, R, Sanmamed, MF, Montuenga, L, Calvo, A (2025).

Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy

CANCER RESEARCH. Article. 85(20):3910-3929.
[doi:10.1158/0008-5472.CAN-24-2772]

Alvarez-Perez, JC, Sanjuán-Hidalgo, J, Arenas, AM, Hernández-Navas, I, Benitez-Cantos, MS, Andrades, A, Calabuig-Fariñas, S, Jantus-Lewintre, E, Paz-Ares, L, Ferrer, I, Medina, PP (2025).

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

NATURE COMMUNICATIONS. Article. 16(1).
[doi:10.1038/s41467-025-62350-4]

Cirauqui, C, Ojeda, L, Otano, I, Pazos, I, Santos, A, Garrido-Martín, EM, Yagüe, P, Ramos-Paradas, J, Molina-Pinelo, S, Roncador, G, Solórzano, JL, Muñoz, MT, Cozar, P, Plaza, P, Suárez, R, Jiménez, M, Moreno, R, Rosado, A, Gámez, P, García-Luján, R, Zugazagoitia, J, Sweet-Cordero, EA, Barbacid, M, Carnero, A, Ferrer, I, Paz-Ares, L (2025).

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

Clinical and Translational Medicine. Article. 15(7).
[doi:10.1002/ctm2.70374]

2024

Jiménez-Reinoso, A, Molero-Abraham, M, Cirauqui, C, Blanco, B, Garrido-Martin, EM, Nehme-Alvarez, D, Domínguez-Alonso, C, Ramírez-Fernández, A, Díez-Alonso, L, Nuñez-Buiza, A, González-Murillo, A, Tobes, R, Pareja, E, Ramírez-Orellana, M, Rodriguez-Peralto, JL, Ferrer, I, Zugazagoitia, J, Paz-Ares, L, Alvarez-Vallina, L (2024).

CD4⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

OncoImmunology. Article. 13(1):2392897-2392897.
[doi:10.1080/2162402X.2024.2392897]

Molina-Pinelo S, Ferrer Sánchez I, Najarro P, Paz-Ares L, Fernández L, Castelló N, Richart López LA, Rodríguez Gambarte JD, Sanz García M, Salinas A, Suárez R, Romero-Romero B, Martín-Juan J, Viñuela ME, Butler RG, de Pedro N (2024).

Telomere-based risk models for the early diagnosis of lung cancer.

Heliyon. Article. 10(24):41040-41040.
[doi:10.1016/j.heliyon.2024.e41040]

Sánchez-Ortega M, Garrido A, Cirauqui C, Sanz-Gonzalez L, Hernández MC, González-García A, Obregon K, Ferrer I, Paz-Ares L, Carrera AC (2024).

A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma.

Redox Biology. Article. 75:103305-103305.
[doi:10.1016/j.redox.2024.103305]

Figarol, S, Delahaye, C, Gence, R, Doussine, A, Cerapio, JP, Brachais, M, Tardy, C, Béry, N, Asslan, R, Colinge, J, Villemin, JP, Maraver, A, Ferrer, I, Paz-Ares, L, Kessler, L, Burrows, F, Lajoie-Mazenc, I, Dongay, V, Morin, C, Florent, A, Pagano, S, Taranchon-Clermont, E, Casanova, A, Pradines, A, Mazieres, J, Favre, G, Calvayrac, O (2024).

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies

NATURE COMMUNICATIONS. Article. 15(1):5345-5345.
[doi:10.1038/s41467-024-49360-4]

2023

Macaya, I, Roman, M, Welch, C, Entrialgo-Cadierno, R, Salmon, M, Santos, A, Feliu, I, Kovalski, J, Lopez, I, Rodriguez-Remirez, M, Palomino-Echeverria, S, Lonfgren, SM, Ferrero, M, Calabuig, S, Ludwig, IA, Lara-Astiaso, D, Jantus-Lewintre, E, Guruceaga, E, Narayanan, S, Ponz-Sarvise, M, Pineda-Lucena, A, Lecanda, F, Ruggero, D, Khatri, P, Santamaria, E, Fernandez-Irigoyen, J, Ferrer, I, Paz-Ares, L, Drosten, M, Barbacid, M, Gil-Bazo, I, Vicent, S (2023).

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

NATURE COMMUNICATIONS. Article. 14(1).
[doi:10.1038/s41467-023-41828-z]

Ramos, AS, Sánchez, DG, Expósito, PP, Paz-Ares, L, Sánchez, IF (2023).

Understanding the basis for intrinsic resistance to KRASG12C inhibitors

ANNALS OF ONCOLOGY. Meeting Abstract. 34:753-753.
[doi:10.1016/j.annonc.2023.09.788]

Marrugal, A, Ferrer, I, Quintanal-Villalonga, A, Ojeda, L, Pastor, MD, García-Lujan, R, Carnero, A, Paz-Ares, L, Molina-Pinelo, S (2023).

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

International Journal Of Molecular Sciences. Article. 24(18).
[doi:10.3390/ijms241813830]

Terapias Dirigidas para la Oncología de Precisión

Publicaciones

2025

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer

Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

2024

CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

Telomere-based risk models for the early diagnosis of lung cancer.

A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma.

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies

2023

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Understanding the basis for intrinsic resistance to KRASG12C inhibitors

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

CD4⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts